While our study provides novel findings that αSMA+ PLV-LMC coverage is reduced in TNF-Tg mice with severe arthritis, and that this reduced coverage persists without turnover or recovery following effective anti-TNF therapy, our study has notable limitations. This evidence concerns the gene ACTA1 and arthritic joint disease.